
Hematology-OncologyRNA SplicingPRMT9
Targeting PRMT9 to Overcome Venetoclax Resistance in AML: A Paradigm Shift in Therapeutic Strategy
By MedXY|Sep 13, 2026
PRMT9-mediated arginine methylation drives venetoclax resistance in AML by altering RNA splicing and protein synthesis. Targeting PRMT9 restores venetoclax sensitivity, offering a promising approach to combat resistant AML.
